GlassScriptPhysician profile
Jillian Mcclintock
NPI 1992306609
$3,852.39
in general payments reported to CMS, 2019-2025
41 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $154 · 2023: $816 · 2024: $1,541 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,239 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,239.19 |
| Education | $203.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $754.37 | 2023-2025 | Rybrevant, Tecvayli, Akeega |
| Astrazeneca Pharmaceuticals LP | $365.17 | 2022-2025 | Enhertu, Tagrisso, Calquence |
| Novartis Pharmaceuticals Corporation | $330.56 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $277.26 | 2021-2024 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $201.34 | 2023-2025 | Libtayo |
| Seagen INC. | $181.38 | 2021-2023 | Tukysa |
| E.R. Squibb & Sons, L.L.C. | $141.83 | 2022 | |
| Abbvie INC. | $124.08 | 2024-2025 | |
| Kite Pharma, INC. | $116.34 | 2024 | |
| Lilly USA, LLC | $107.08 | 2024 | Verzenio |
| Merck Sharp & Dohme LLC | $82.82 | 2024-2025 | Keytruda, Welireg |
| Exelixis INC. | $78.94 | 2024-2025 | Cabometyx |
| Gilead Sciences, INC. | $74.81 | 2023-2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $67.81 | 2024-2025 | Onivyde |
| Pfizer INC. | $66.46 | 2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $65.94 | 2024 | Pomalyst |
| Eisai INC. | $51.10 | 2023-2024 | |
| Genmab U.S., INC. | $49.46 | 2024-2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $45.20 | 2023-2024 | |
| Mirati Therapeutics, INC. | $43.29 | 2023-2024 | Krazati |
| Blueprint Medicines Corporation | $42.03 | 2024 | Ayvakit |
| Incyte Corporation | $41.66 | 2024-2025 | Jakafi, Pemazyre, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $41.64 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $39.53 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Beigene USA, INC. | $39.31 | 2024 | Tevimbra, Brukinsa |
| Amgen INC. | $38.66 | 2021-2023 | Vectibix, Nplate, Xgeva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.98 | 2024 | Gilotrif |
| Genzyme Corporation | $35.31 | 2024 | |
| Accord Healthcare, INC. | $31.32 | 2025 | |
| Boston Scientific Corporation | $30.35 | 2025 | Watchman Flx |
| Kyowa Kirin, INC. | $29.65 | 2024 | Poteligeo |
| Verity Pharmaceuticals INC. | $27.94 | 2024 | Trelstar |
| Daiichi Sankyo INC. | $27.59 | 2025 | Enhertu |
| Emd Serono, INC. | $26.02 | 2024 | |
| Alnylam Pharmaceuticals INC. | $24.99 | 2024 | Givlaari |
| G1 Therapeutics, INC. | $23.27 | 2023 | Cosela |
| Sobi, INC | $21.28 | 2025 | |
| Taiho Oncology, INC. | $20.22 | 2024 | |
| Genentech USA, INC. | $16.68 | 2023 | Tecentriq |
| Beone Medicines USA, INC. | $16.07 | 2025 | Tevimbra |
| Tersera Therapeutics LLC | $15.65 | 2025 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Mcclintock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.